Table 2 Clinical characteristics of patients based on emphysema score.
From: Centrilobular emphysema combined with pulmonary fibrosis results in improved survival
| Variable |
ES 0 (n= 48) |
0 < ES ≤ 2 (n= 26) |
ES > 2 (n= 28) | P value |
|---|---|---|---|---|
| Age years; median [1st, 3rd] | 62 [58, 68] | 61 [53, 67] | 57 [51, 62] | NS* |
| Gender: | ||||
|
Male, n Female, n |
31 17 |
18 8 |
17 11 | NS† |
| Race: | ||||
| Caucasian, n | 38 | 15 | 16 | |
| African-American, n | 8 | 9 | 11 | NS† |
| Other, n | 2 | 2 | 1 | |
| Medication: | ||||
| Prednisone, n | 40 | 26 | 22 | NS† |
| Azathioprine, n | 24 | 13 | 12 | NS† |
| Mycophenolate, n | 14 | 9 | 4 | NS† |
| N-Acetylcysteine, n | 22 | 13 | 7 | NS† |
| ACE Inhibitor, n | 10 | 6 | 3 | NS† |
| Statin, n | 20 | 14 | 11 | NS† |
| Smoking: | ||||
| Current smoker, n (%) | 1(2) | 2 (7) | 4 (14) | NS† |
| Ever-smoker, n (%) | 27 (56) | 21 (81) | 24 (86) | < 0.01† |
| Pack/years, median [ 1st, 3rd] | 5 [0, 20] | 20 [10, 39] | 40 [20, 50] | < 0.0001* |
| Fibrosis score: | ||||
| < 10%, n | 7 | 5 | 2 | |
| 10 - 40%, n | 27 | 16 | 19 | NS† |
| > 40%, n | 14 | 5 | 7 | |
| Right heart catheterization: | ||||
| Performed, n (%) | 37 (77) | 22 (84) | 17 (61) | NS† |
| Mean PAP mm Hg; median [ 1st, 3rd] | 21 [18, 24] | 29 [22, 40] | 29 [22, 33] | < 0.001* |
| Surgical lung biopsy: | ||||
| Performed, n (%) | 36 (75) | 17 (65) | 20 (71) | NS† |
| UIP, n | 32 | 14 | 14 | NS† |
| Fibrotic NSIP, n | 4 | 3 | 6 | |
| Lung transplantation performed, n (%) | 19 (39) | 6 (23) | 9 (32) | NS† |